Drug discontinuation: Mesalamine Capsule, Extended Release (MESALAMINE, PENTASA)
FDA lists 3 presentations as To Be Discontinued. Companies: Mylan Pharmaceuticals Inc., a Viatris Company, Takeda Pharmaceuticals USA Inc..
- Published by source
- 2026-08-25
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-23
Affected
- Manufacturer
- Mylan Pharmaceuticals Inc., a Viatris Company
- Products
- Mesalamine Capsule, Extended Release MESALAMINE PENTASA
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacture of the drug
- Product is anticipated to be available until December 31, 2027
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-08-25
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #982 | new | 2026-10-22 | 6ee00cd3472d…1668c0 | b453f3ac5a87…39026c |
| #1207 | update | 2026-10-23 | a7e63e8110da…249032 | 9882ddc82784…b6f806 |
Chain head: #1250 0c9a4a81d7d8…29590d